Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.620
+0.030 (0.65%)
At close: Jul 10, 2026, 4:00 PM EDT
4.723
+0.103 (2.23%)
After-hours: Jul 10, 2026, 5:21 PM EDT
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $44.14M in the quarter ending March 31, 2026, with 6.46% growth. This brings the company's revenue in the last twelve months to $204.17M, up 3.61% year-over-year. In the year 2025, Cytek Biosciences had annual revenue of $201.49M with 0.52% growth.
Revenue (ttm)
$204.17M
Revenue Growth
+3.61%
P/S Ratio
2.92
Revenue / Employee
$301,137
Employees
678
Market Cap
596.64M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 201.49M | 1.04M | 0.52% |
| Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
| Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
| Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
| Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
| Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
| Dec 31, 2019 | 57.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 825.37M |
| Tactile Systems Technology | 343.52M |
| Viemed Healthcare | 286.57M |
| OrthoPediatrics | 243.30M |
| Cerus | 216.56M |
| Pacific Biosciences of California | 160.03M |
| Beta Bionics | 110.24M |
| NeuroPace | 99.53M |
CTKB News
- 26 days ago - Cytek Biosciences Transcript: Singular Research’s Las Vegas Invitational Conference - Transcripts
- 26 days ago - Cytek Biosciences Slides: Singular Research’s Las Vegas Invitational Conference - Filings
- 4 weeks ago - Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference - GlobeNewsWire
- 4 weeks ago - Cytek Biosciences Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 - GlobeNewsWire
- 2 months ago - Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens - TheFly
- 2 months ago - Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley - TheFly
- 2 months ago - Cytek Biosciences Earnings Call Transcript: Q1 2026 - Transcripts